AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
William Blair Maintains Sell Rating on Ginkgo Bioworks Holdings
ByAinvest
Saturday, Aug 9, 2025 8:31 am ET1min read
Ginkgo Bioworks Holdings (DNA) received a Sell rating from William Blair analyst Matt Larew, who maintains an average return of -8.1% and a 38.33% success rate on recommended stocks. The current analyst consensus is a Moderate Sell with an average price target of $10.00. DNA's market cap is $817.1M and has a P/E ratio of -1.50.
Ginkgo Bioworks Holdings Inc (DNA) reported a quarterly adjusted loss of $1.10 per share for the period ending June 30, 2025, according to a Reuters news article [2]. This loss is higher than the same quarter last year when the company reported an EPS of $-2.80. The mean expectation of three analysts for the quarter was for a loss of $1.57 per share, with Wall Street's median 12-month price target standing at $8.00, about 68.3% below its last closing price of $13.46 [2].Revenue for the quarter fell by 11.7% to $49.60 million from a year ago, compared to analysts' expectations of $41.61 million. The company reported a quarterly loss of $60.3 million. Despite the financial setback, shares of Ginkgo Bioworks Holdings Inc have seen a significant increase, rising by 24.1% this quarter and gaining 42.2% so far this year [2].
The current analyst consensus is a Moderate Sell with an average price target of $10.00. William Blair analyst Matt Larew recently issued a Sell rating for the company, citing an average return of -8.1% and a 38.33% success rate on recommended stocks [1]. The company's market cap is $817.1M with a P/E ratio of -1.50 [1].
In the last three months, the mean earnings estimate of analysts had risen by about 5.2%, with no earnings estimate revisions in the last 30 days. The current average analyst rating on the shares is "sell," with a breakdown of recommendations including 1 "strong buy" or "buy," no "hold," and 3 "sell" or "strong sell" [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TX3Q8:0-ginkgo-bioworks-holdings-inc-expected-to-post-a-loss-of-1-57-a-share-earnings-preview/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U00S8:0-ginkgo-bioworks-holdings-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet